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Abstract
Background: DNA microarray technology is a powerful technique that was recently developed
in order to analyze thousands of genes in a short time. Presently, microarrays, or chips, of the
cDNA type and oligonucleotide type are available from several sources. The number of
publications in this area is increasing exponentially. 
Results: In this study, microarray data obtained from two different commercially available systems
were critically evaluated. Our analysis revealed several inconsistencies in the data obtained from
the two different microarrays. Problems encountered included inconsistent sequence fidelity of the
spotted microarrays, variability of differential expression, low specificity of cDNA microarray
probes, discrepancy in fold-change calculation and lack of probe specificity for different isoforms of
a gene.
Conclusions: In view of these pitfalls, data from microarray analysis need to be interpreted
cautiously.
Background
Traditionally, techniques for the study of gene expression
were significantly limited in both breadth and efficiency
since these studies typically allowed investigators to study
only one or a few genes at a time. However, the recently
developed DNA microarray technique is a powerful meth-
od that provides researchers with the opportunity to ana-
lyze the expression patterns of tens of thousands of genes
in a short time [1]. Presently, several vendors offer these
microarray systems, also known as chips, with a variety of
technologies available. Currently, DNA microarrays are
manufactured using either cDNA or oligonucleotides as
gene probes. cDNA microarrays are created by spotting
amplified cDNA fragments in a high density pattern onto
a solid substrate such as a glass slide [1,2]. Oligonucle-
otide arrays are either spotted or constructed by chemical-
ly synthesizing approximately 25-mer oligonucleotide
probes directly onto a glass or silicon surface using photo-
lithographic technology [3].
Due to the powerful nature of microarrays, the number of
relevant publications in this burgeoning field is increasing
exponentially. During the years 1995–1997, the number
of reports featuring microarray data was less than ten.
However, in 2001 alone approximately 800 publications
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to a PubMed search).
Microarray technology certainly has the potential to great-
ly enhance our knowledge about gene expression, but
there are drawbacks that need to be considered. As Knight
[4] cautioned, it is possible that errors could be incorpo-
rated during the manufacture of the chips. Consequently,
the fidelity of the DNA fragments immobilized to the
microarray surface may be compromised. However, there
are few studies where the majority of the gene sequences
spotted on the microarrays were verified [5]. Kuo et al
(2002) compared the data from two high-throughput
DNA microarray technologies, cDNA microarray (Stan-
ford type) and oligonucleotide microarray (from Affyme-
trix) and found very little correlation between these two
platforms [6]. Unfortunately, many investigators are re-
porting microarray data without confirming their results
by other traditional gene expression techniques such as
PCR, Northern blot analysis and RNase protection assay.
Raw microarray data obtained from questionable nucle-
otide sequences are then often manipulated using cluster
and statistical analysis software and subsequently report-
ed in scientific journals. In addition the quality of the
probe sequences and the location of the probes selected
for incorporation into the array are also very important.
For example, if probes are selected only from the 3' end of
a given gene, then there is a strong possibility that differ-
ent splice variants of that gene will not be identified if the
alternative splicing occurs at the 5' region of the gene.
The development of a single chip containing the complete
gene set for a given tissue or for a complex organism
(30,000 to 60,000 genes) is likely in the near future, so it
is paramount that chip manufacturers avoid these prob-
lems [7]. In this report, we demonstrate that microarray
technology continues to be a dynamic and developing
process and highlight potential pitfalls that must be ad-
dressed when interpreting data.
Results
Inconsistent sequence fidelity of spotted cDNA microar-
rays
cDNA microarray analysis was performed using the Uni-
GEM-V chip (IncyteGenomics, Palo Alto, CA) with mRNA
isolated from peripheral blood mononuclear cells (PB-
MC) of a large granular lymphocyte leukemia patient and
a healthy control. In this microarray, 7075 immobilized
cDNA fragments (4107 from known genes and 2968
ESTs) were immobilized onto a glass slide. After careful
examination of the microarray probes, it was determined
that the majority of the spotted cDNA fragments were
from the 3' end of the genes. Approximately 80 up-regu-
lated and 12 down-regulated genes were identified in
leukemic LGL. We then purchased seventeen clones from
IncyteGenomics containing cDNA fragments that repre-
sent fourteen of the up-regulated and three of the down-
regulated genes. Plasmid DNA was isolated from the
clones and the sequences were verified. Unfortunately, we
found several problems with the insert DNA sequences in
these clones. Four of the seventeen c DNA fragments spot-
ted on the microarray contained incorrect sequences
(23.5%) (Table 1).
Variable reliability of differential expression data
The cDNA fragments corresponding to differentially ex-
pressed genes spotted on the microarrays were excised
from the plasmid DNA and used as probes in Northern
blots. Out of the seventeen only eight provided positive
results as indicated by microarray (47%). Although all the
sequences for the down-regulated genes were correct,
Northern blot analysis with these probes did not show
any differential expression of the genes. This is in contrast
to the microarray data that suggested they were down reg-
ulated (Table 1).
Low specificity of cDNA microarray probes
By microarray analysis, it is very difficult to distinguish be-
tween two genes that share a high degree of sequence sim-
ilarity. Low specificity of probes is also a frequently
encountered problem in oligonucleotide arrays. This
problem is especially prevalent in instances where DNA
sequences are nearly identical between two genes and the
oligonucleotide probes are generated from the 3' end of
the genes. For example, the 1.2 kb fragment (GB Accession
No. M 57888) spotted on the cDNA microarray as
granzyme B was not able to distinguish between granzyme
B and H (Fig. 1a). The balanced differential expression of
6.3 was calculated. A probe set was generated by Affyme-
trix using the similar sequence information (GB Accession
No.M28879) and according to oligonucleotide array,
granzyme B was shown to be up-regulated (fold change
21.5: Fig. 1b). Northern blot analysis (using the same frag-
ment as probe) did not discriminate between the genes for
granzyme B versus granzyme H (Fig. 1c). However, by using
gene-specific probes in an RNase protection assay, we
were able to demonstrate the over-expression of granzyme
B and granzyme H separately in leukemic LGL cells (Fig. 1d
and 1e).
Discrepancy in fold change calculation for a given gene
It is very difficult to compare the exact fold change be-
tween two microarray techniques, and no standard value
system is currently in place to compare the changes found
in one microarray to the next. This fact was clearly demon-
strated by Kuo et al (2002) in their recent publication [6].
In this paper we compared the fold change (Affymetrix)
and balanced differential expression (cDNA) with North-
ern blot expression. For example, our IncyteGenomics
cDNA microarray data demonstrated only a 3.8 differen-Page 2 of 10
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pore-forming protein produced by cytolytic lymphocytes
[8] in leukemic LGL cells, whereas the oligonucleotide
microarray indicated a 103 fold increase (Fig. 2b). Using
a probe identical to the one spotted on the cDNA micro-
array, we performed a Northern blot analysis. The blot
demonstrated the up-regulation of the perforin transcript
in leukemia LGL cells (Fig. 2c), but the fold increase was
neither 103 as indicated by oligonucleotide array nor 3.8
as determined by the cDNA microarray data. Instead, the
Figure 1
a). A portion of a scanned cDNA microarray showing the differential expression of granzyme H. The cDNA frag-
ment spotted on position F12 corresponds to granzyme H (indicated by arrow). (I). Hybridization profile for LGL leukemia
cells. (II). Hybridization profile for control. Balanced differential expression, 6.3. b). Shows the differential expression of
Granzyme B in oligonucleotide array. Calculated fold change is 20.5 (I). Hybridization pattern for the granzyme B probe
set (with RNA isolated from normal PBMC), PM = Perfect match, MM = Mismatch. (II). Hybridization pattern for the granzyme
B probe set (with RNA isolated from leukemic LGL), PM = Perfect match, MM = Mismatch c). Northern blot showing
expression of granzyme B/H. The probe used was the same as the probes spotted on the microarray. Lane LGL = total
RNA samples isolated from LGL leukemia patient Lane N =  total RNA isolated from normal healthy control. NA = Total RNA
isolated from PBMC of a normal healthy individual activated with IL2 and PHA. d). RNase protection assay for granzyme
B. Probe set hAPO-4 obtained from PharMingen contains a specific probe for granzyme B. Note: Leukemic LGL cells over-
expressed granzyme B (Lane LGL), whereas very low levels of granzyme B were observed in PBMC from normal healthy con-
trol (Lane N). Normal activated PBMC showed strong expression of granzyme B (Lane NA). e). RNase protection assay
for granzyme H. Probe set hAPO-4 obtained from PharMingen contains a specific probe for granzyme H. Leukemic LGL cells
showed over-expression (Lane LGL). PBMC obtained from a normal healthy individual (Lane N) and activated PBMC showed
trace expression.Page 3 of 10
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treme values. These observations strongly suggest that re-
sults for significantly altered genes should be confirmed
with other traditional techniques such as Northern blots
or RNase protection assays prior to reporting the fold in-
crease.
Lack of probe specificity for gene isoforms
One of the genes spotted on the cDNA microarray that we
are interested in is (Phosphatase in Activated Cells) PAC-
1[9]. The differential expression of PAC-1 by both cDNA
microarray (differential expression 4.2) and oligonucle-
otide arrays (fold change 1.6) is shown in Figures 3a and
3b. Using a cDNA fragment identical to the PAC-1 probe
on the cDNA microarray, we performed a Northern blot
analysis and confirmed the over-expression of two tran-
scripts in leukemic LGL cells (Fig. 3c). RT-PCR was per-
formed using total RNA from leukemic LGL and specific
probes designed to amplify full-length PAC-1. We did not
see amplification of any product. In addition, we found
no PAC-1 expression using two different monoclonal
anti-PAC-1 antibodies in Western blot analysis (data not
shown). The monoclonal antibodies obtained from Santa
Cruz were based on the amino acid sequence information
obtained from the N-terminus and C-terminus of the
PAC-1. The results of all the experiments did not confirm
the over-expression of PAC-1. Therefore, to obtain more
information about the structure of the PAC-1 related
genes in leukemic LGL, we screened an LGL leukemia
cDNA library using a 1.2 kb PAC-1 cDNA fragment and
identified similar genes which are different forms of PAC-
1 (GenBank Accession #AF331843, the other sequence is
not deposited). Similarly an anti-apoptotic gene A20 is
also over-expressed in leukemic LGL, but protein expres-
sion was absent when Western blots were performed with
monoclonal antibodies raised against the amino acid se-
quence derived from A20 (data not shown).
Likewise, another gene of interest, NKG2 C, showed a bal-
anced differential expression of 5.5 (Fig. 4a). By using a
probe derived from an NKG2 C clone, we identified a
number of transcripts by Northern blot analysis (Fig. 4b).
In order to ascertain more structural information, we
again screened the LGL leukemia library and identified
the presence of several members of the NKG2 gene family
including NKG2 A, NKG2 D, NKG2 E and NKG2 F (GB Ac-
cession Nos. AF461812, AF461811, AF461157) [10].
Therefore, if genes similar to NKG2 family members are
spotted on a microarray, it may be difficult to confirm
which form of the gene is differentially expressed in a giv-
en sample.
Mismatch probe sets mask the perfect match signals in ol-
igonucleotide array (Affymetrix)
In order to accomplish the highest sensitivity and specifi-
city in the presence of a complex background, Affymetrix
introduced a system that entails the use of a series of spe-
cific and non-specific gene probe sets that are intended to
result in a more accurate discrimination between true sig-
nal and random hybridization. Each probe set consists of
a pair of 25-mer probes, one that represents a perfect
match (PM)to the mRNA of interest, and a second probe
Table 1: Verification of genes spotted on cDNA microarray






EST 0. 250 17.7 correct negative
EST 11.8 incorrect negative
Granzyme H 1.2 6.3 correct positive
NKG2C 1.5 5.5 correct positive
Lymphopain 1.2 5.4 correct positive
Interferon RF 0.8 5.0 incorrect -------
SCFM ----- 4.6 correct positive
Pac-1 1.2 4.2 correct positive
Perforin 0.6 3.8 correct positive
A-20 0.6 3.2 correct positive
CHK 3.2 incorrect ------
GCSF 2.4 3.1 incorrect ------
EST 0.250 3.1 correct positive
Com.comp. C2 1.8 2.8 correct negative
IHH 0.9 -18.6 correct negative
H transport 1.5 -10.4 correct negative
Ribo.26 0.4 -6.2 correct negativePage 4 of 10
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The mismatch in the middle position theoretically pro-
vides maximal disruption of hybridization. Unfortunate-
ly, the use of the mismatch probe information can
interfere with fold change calculations of gene expression.
For example, perforin transcripts showed strong hybridiza-
tion to both PM and MM probe sets. As a consequence,
the strong MM signal masked the PM signal resulting in a
low expression readout, even though the gene was present
in normal PBMC (Fig. 2b). Therefore, the subsequently
calculated fold increase from the test sample was extraor-
dinarily high and deemed unreliable. Similarly, the fold
change calculation was underestimated for PAC-1 due to
the strong signal displayed for MM probe set (Fig. 3b).
Genes such as human auto-antigen (GenBank Accession
#L26339) and carboxyl ester lipase-like protein (GenBank
Accession #L14813), are additional examples where these
genes are present in LGL sample, but because of the strong
signals associated with some of the MM probes, they are
considered absent in the samples (Fig. 5a and 5b).
Figure 2
a). A portion of a scanned cDNA microarray showing the differential expression of perforin in the cDNA
microarray. Arrow indicates the position of spots corresponding to perforin (D2). Differential expression is only 3.8 b).
Shows the differential expression of perforin in oligonucleotide array. Calculated fold change is 103. (I). Hybridization
pattern for the perforin probe set (with RNA isolated from normal PBMC), PM = Perfect match, MM = Mismatch. (II). Hybrid-
ization pattern for the perforin probe set (with RNA isolated from leukemic LGL), PM = Perfect match, MM = Mismatch Note:
Even though the gene is present in trace amounts in PBMC, it is calculated as absent because of the high background caused by
MM hybridization. c). Northern blot showing the expression of perforin. Lane LGL = total RNA obtained from leukemic
LGL. Lane N = total RNA isolated from normal healthy individuals. Sample from LGL leukemia patients showed over-expres-
sion of perforin.Page 5 of 10
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In order to identify the differentially expressed genes in
large granular lymphocytic (LGL) leukemia, we per-
formed microarray analysis using the UniGEM-V microar-
ray from IncyteGenomics and the HU6800
oligonucleotide array from Affymetrix. In the course of
our analysis, we discovered several problems that we feel
could occur in other studies that might lead to false con-
clusions.
Approximately 80 up-regulated genes and 12 down-regu-
lated genes were identified by cDNA microarray analysis
in leukemic LGL cells. Since microarray technology was a
new tool at that time, we decided to verify the sequences
of all the genes that were differentially expressed. To that
end, we purchased approximately 20 clones representing
the differentially expressed genes and verified the se-
quences. We found that only approximately 70% of the
genes spotted on the microarray matched the correct se-
quence of the clones. Other groups reported similar obser-
vations. For example, IMAGE mouse cDNA clones
(approximately 1200) were purchased from Research Ge-
netics (Huntsville, Alabama) and sequences were verified
by Halgren et al [11]. This group found that only 62%
were definitely identified as a pure sample of the correct
clones. In another study, PCR amplification products
Figure 3
a). A portion of a scanned cDNA microarray showing the differential expression of PAC-1. The cDNA fragment
spotted on position E6 corresponds to PAC-1. (I) Hybridization pattern for LGL patient. (II). Hybridization pattern for control.
b). Shows the differential expression of PAC-1 in oligonucleotide array. Calculated fold change is 1.6 (I) Hybridization
pattern for the PAC-1 probe set (RNA isolated from normal PBMC. PM = Perfect Match, MM = Mismatch. (II) Hybridization
pattern for the PAC-1 probe set (RNA isolated from leukemic LGL cells. PM = Perfect Match, MM = Mismatch. c). Northern
blot showing the expression of PAC-1 like genes. The probe used was the same as the one spotted on the microarray.
Lane LGL = total RNA isolated from LGL leukemia patients (LGL). Lane N = total RNA isolated from normal healthy controls.Page 6 of 10
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quenced and only 79% of the clones matched the original
database [12]. In a different study, it was estimated that
only 80% of the genes in a set of microarray experiments
were correctly identified [5]. Therefore, we advise that
when preparing cDNA microarrays (commercial or home-
made), it is necessary to sequence verify each clone at the
final stage before printing the microarray. If mistakes are
made at this stage, it is not possible to correct them later
by using the most sophisticated analytical tools.
We used cDNA microarray analysis to compare the gene
expression profile of leukemic LGL cells obtained from a
patient versus the expression profile of PBMC obtained
from a normal healthy individual as a control. We decided
to verify the microarray results using samples from more
patients by employing the use of other methods such as
PCR, Northern blot and RNase protection assay. To our
surprise, none of the three down-regulated genes studied
exhibited differential expression in Northern blots when
the cDNA fragments of these genes were used as probes. In
the up-regulated genes, only 47 % proved to support the
results from the microarray data. The rest either displayed
no signal, were not detectable in any sample or failed to
reveal any differential expression whatsoever. Although
some genes such as PAC-1 and A20 showed differential ex-
pression in LGL leukemia patients, no product amplifica-
tion was obtained using RT-PCR with gene-specific
primers.
Figure 4
a). A portion of a scanned cDNA microarray showing the differential expression of NKG2 C. The cDNA fragment
spotted on position H11 correspond to NKG2 C. (I) Hybridization pattern for LGL patient. (II). Hybridization pattern for con-
trol. b). Northern Blot showing the expression of NKG2 family members. The probe used was the same as the one
spotted on the microarray. Lane LGL = total RNA isolated from LGL leukemia patients (LGL). Lanes N = total RNA isolated
from normal healthy controls.Page 7 of 10
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tween two similar genes. The best example in our case is
when granzyme B and granzyme H are compared. These
two genes share approximately 80% similarity at the DNA
level but have different enzymatic activities [13,14]. Using
either one of the genes as a probe, both cDNA microarray
and northern blot analysis indicated over-expression of
both genes indiscriminately (Fig. 1). However, using
gene-specific probes in an RNase protection assay, we
were able to distinctly identify the over-expression of both
granzyme B and H in leukemic LGL cells (Fig. 1d and 1e).
In normal PBMC only trace amounts of both genes were
identified, but after activation by PHA and IL2 only
granzyme B was up-regulated. It is very difficult to get this
information by microarray analysis alone. Therefore, cau-
tion in presenting microarray data without verification
and confirmation is advised.
When the results from two different microarray technolo-
gies (cDNA and oligonucleotide arrays) were compared,
the differential expression in some of the genes appeared
to agree in both cases but a large variation in expression
profiles between the two microarrays was clearly evident.
Previously, such systematic differences in the two technol-
ogies were reported [6]. For example, perforin showed a
103-fold change in the Affymetrix array, whereas the
cDNA microarray showed only a balanced differential ex-
pression of 3.8-fold. Northern blot results indicate that
the genes were over-expressed, but the actual value is in
between the values from the two microarrays. This prob-
lem may be due to an inaccurate fold change calculation
due to the inclusion of mismatch values in the formula.
We observed that many over-expressed genes were not
properly identified at times. This may be the result of the
introduction of mismatch values in the Affymetrix system.
For example, genes for human autoantigen and human car-
boxyl ester lipase-like protein would be considered up-regu-
lated in the microarray (according to PM match
hybridization) if the MM hybridization values were ig-
nored in the fold change calculation.
DNA microarray anlysis can be a powerful technique to
identify differentially expressed genes but differentiating
between splice variants can be problematic. For example,
although the differential expression of the several genes
such as PAC-1 and A20 were confirmed by northern blot
analysis, we were unable to see any expression of protein
corresponding to these genes by Western blot analysis. We
were also unable to amplify those genes using gene-specif-
ic primers by RT-PCR. After screening the LGL library, we
obtained several full-length genes that were different from
both the 5' and 3' ends of PAC1. Similarly, we screened an
LGL leukemia library and obtained several 1.5 kb cDNA
fragments using the A20 cDNA as a probe. The deduced
amino acid sequences of these genes revealed different
proteins.
We found an up-regulation of NKG2C with a balanced dif-
ferential expression of 5.8 in cDNA microarray (Fig. 4a).
When Northern Blot analysis was performed using NKG2
C cDNA as a probe, we identified multiple transcripts.
Screening the LGL leukemia library resulted in the identi-
fication of several other members of the NKG2 family
such as NKG2 A, D, E, and F[10]. Therefore, it can be very
difficult to distinguish different forms of genes if they are
similar in certain sequence regions.
Conclusions
At the time of writing this report there were approximately
1150 articles published describing microarray results
(PubMed). There is no doubt that these results will pro-
vide an overall idea of gene expression and contribute to
Figure 5
a). Hybridization pattern for the human autoantigen probe set (with RNA isolated from normal PBMC), PM = Perfect
match, MM = Mismatch. b). Hybridization pattern for probe set human carboxy ester lipase-like protein (with RNA
isolated from leukemic LGL. PM = Perfect match, MM = Mismatch Note: Even though the gene is present in trace amounts, it
is calculated as absent because of the high background caused by MM hybridization.Page 8 of 10
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various processes. However, as demonstrated by our find-
ings, the development of a standardized microarray sys-
tem is needed to obtain more meaningful data from these
experiments. The introduction of more uniform systems
combined with the consideration of the above described
pitfalls and alternatives will allow better utilization of this
powerful technique in an expanding collection of scientif-
ic endeavors. It will be very helpful for the scientific com-
munity if the verified data is deposited in a public data
base.
Methods
Isolation of PBMC and RNA
PBMC were isolated from whole blood using Ficoll-Hy-
paque density gradient centrifugation. These cells were
suspended in Trizol reagent (GIBCO-BRL, Rockville, MD)
and total RNA was isolated immediately according to the
manufacturer's instructions. Poly A+ RNA was isolated
from total RNA by using Oligo-Tex mini mRNA kit (Qia-
gen, Valencia, CA) according to the manufacturer's recom-
mendations.
Activation of PBMC
Normal PBMC were cultured in vitro and activated by
PHA, (Sigma Chemical Co. St. Louis, MO) (1 µg/ml, 2
days) and Interleukin-2 (IL-2) (100 U/ml, 10 days), then
total RNA was isolated.
cDNA microarray analysis
Microarray probing and analysis was performed by In-
cyteGenomics. Briefly, one µg of Poly (A) + RNA isolated
from PBMC of an LGL leukemia patient and healthy indi-
vidual was reverse transcribed to generate Cy3 and Cy5
fluorescent labeled cDNA probes. cDNA probes were
competitively hybridized to a human UniGEM-V cDNA
microarray containing approximately 7075 immobilized
cDNA fragments (4107 for known genes and 2968 for
ESTs). Microarrays were scanned in both Cy3 and Cy5
channels with an Axon GenePix scanner (Foster City, CA)
with a 10 µm resolution. P1 and P2 signals are the inten-
sity reading obtained by the scanner for Cy3 and Cy5
channels. The balanced differential expression was calcu-
lated using the ratio between the P1 signal (intensity read-
ing for probe 1) and the balanced P2 signal (intensity
reading for probe 2 adjusted using the balanced coeffi-
cient)
Incyte GEMtools software (Incyte Pharmaceuticals, Inc.,
Palo Alto, CA) was used for image analysis. A gridding and
region detection algorithm determined the elements. The
area surrounding each element image was used to calcu-
late a local background and was subtracted from the total
element signal. Background subtracted element signals
were used to calculate Cy3:Cy5 ratio. The average of the
resulting total Cy3 and Cy5 signal gave a ratio that was
used to balance or normalize the signals.
Oligonucleotide microarray analysis
The HU 6800 microarray was obtained from Affymetrix
(Santa Clara, CA). Briefly, total RNA isolated from normal
PBMC and leukemic LGL were DNase-treated and purified
with a Qiagen kit (Valencia, CA). Approximately 10 µg of
purified RNA was used to prepare double-stranded cDNA
(Supercript GIBCO/BRL, Rockville, MD) using a T7
(dT)24 primer containing a T7 RNA polymerase promoter
binding site. Biotinylated complementary RNA was pre-
pared from 10 µg of cDNA and then fragmented to ap-
proximately 50 to 100 nucleotides. In vitro transcribed
transcripts were hybridized to the HU 6800 microarray for
16 h at 45°C with constant rotation at 60 rpm. Chips were
washed and stained by using the Affymetrix fluidics sta-
tion. Fluorescence intensity was measured for each chip
and normalized to the fluorescence intensity for the entire
chip.
Verification of the clones
GEM cDNA clones (supplied as a bacterial stab) were pur-
chased from IncyteGenomics and streaked on LB agar
plates containing the appropriate antibiotic. Individual
colonies were picked and grown in LB medium. Plasmid
DNA was isolated and sequenced in order to verify the se-
quence identity.
Northern blot analysis
Northern Blotting was performed as described. Briefly 10
µg of total RNA from each sample was denatured at 65°C
in RNA loading buffer, electrophoresed in a 1% agarose
gel containing 2.2 M formaldehyde, then blotted onto a
Nytran membrane (Schleicher & Schuell, Inc, Keene,
N.H). The RNA was fixed to the membrane by UV cross-
linking. cDNA was labeled with [32P] and purified using
Nick columns (Amersham Pharmacia Biotech AB, Piscat-
away, NJ). Hybridization and washing of the blots were
performed as described by Engler-Blum et al [15].
RNase protection assay (RPA)
RPAs were performed using the RNA isolated from leuke-
mic LGL, normal PBMC and normal PBMC activated by
IL-2 and PHA. Five µg of total RNA was hybridized to the
in vitro transcribed hAPO-4 probe set (PharMingen,
SanDiego, CA), and the RPA assay was performed accord-
ing to the manufacturer's protocol. After the assay, the
samples were resolved on a 5% polyacrylamide gel. The
gel was dried and exposed to X-ray film. After developing
the film, the bands were quantitated by using the Image-
Quant program and normalized with the housekeeping
gene, L32.Page 9 of 10
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Cells were lysed in a buffer containing 50 mM Tris-HCl
(pH 7.6), 5 mM EDTA, 150 mM NaCl, 0.5 % NP-40, and
0.5% Triton X-100 containing 1 µg/ml leupeptin, apro-
tinin and antipain; 1 mM sodiumorthovanadate; and 0.5
mM PMSF (all reagents were obtained from Sigma Chem-
ical Co.). Twenty-five µg of total protein from each sample
was subjected to 10% SDS-PAGE. Then the proteins were
transferred to a membrane and Western blotting was per-
formed using the monoclonal antibody for PAC-1 and
A20, followed by the ECL technique as recommended by
the manufacturer (Amersham Biosciences, Piscataway,
NJ).
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